Melatonin: a promising new approach in Alzheimer’s treatment
Melatonin shows promise in Alzheimer’s treatment by restoring circadian rhythms and reducing neurodegenerative symptoms, researchers have demonstrated in a groundbreaking study.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2212 entries already.
Entries by Thomas Gabrielczyk
Giredestrant demonstrates efficacy in early-stage breast cancer
Roche has reported that its selective estrogen receptor degrader (SERD), giredestrant, has demonstrated significant clinical benefit in pivotal Phase III trials for adjuvant early-stage ER-positive, HER2-negative breast cancer, as well as strong efficacy in advanced breast cancer settings. These results position giredestrant as the first oral SERD to show meaningful clinical benefit in this indication. The announcement sparked a notable 7% jump in Roche’s share price in a single day.
Avanzanite secures €32m Series A funding
Dutch Avanzanite Biosciences NV has secured €32 m in a Series A financing round from MVM Partners to scale orphan drug commercialisation across Europe.
MitoRx Therapeutics advances next-generation obesity therapy
MitoRx Therapeutics Ltd has raised £5.5m in a seed financing to advance Myo‑004, a small molecule mitochondrial-targeted obesity therapy enabling fat loss while preserving lean muscle mass.
Sofinnova Partners surpasses target with €650m fund to back up early-stage biotech
Sofinnova Partners has closed its new investment fund, Capital XI, at €650m, far exceeding its original target. The early-stage biotech and medtech-focused fund will invest mostly in Series A, but also seed financings of companies, including oncology, inflammation and immunology, CNS, and cardio-metabolic diseases.
Medicxi announces new €500m biotech investment fund
VC specialist Medicxi has closed its oversubscribed €500m Fund V to support existing biopharmaceutical developers, and creating new companies across all development stages.
AZ’s baxdrostat mets endpoint in resistant hypertension
AstraZeneca’s baxdrostat cuts 24-hour systolic BP by 14mmHg in resistant hypertension, offering a novel mechanism and major market potential.
AstraZeneca bolsters obesity portfolio with muscle‑preserving buy
AstraZeneca plc acquires SixPeaks Bio Inc to target muscle‑preserving obesity therapies, boosting its pipeline in a US$30 bn fast-growing weight-loss market.
Breakthrough study reveals stability key for mRNA
A landmark discovery by a team of South Korean scientists could transform the way RNA-based vaccines and therapeutics are developed and produced. Researchers led jointly by Professor V. Narry Kim and Professor Jin-Hong Kim have identified a series of viral RNA motifs that make conventional messenger RNA (mRNA) far more stable and efficient, potentially revolutionising RNA drug manufacturing.
Semaglutide and tirzepatide significantly improve heart health
Semaglutide (Ozempic®) and Tirzepatide (Mounjaro®) not only promote weight loss but also significantly reduce the risk of major cardiovascular events in patients with type 2 diabetes. Real-world evidence from the Technical University of Munich and Harvard Medical School shows up to 18% lower risk of heart attack and stroke, highlighting the growing potential of GLP-1 therapies in cardiometabolic care.